In the phase 3 SOLO-1 study, olaparib as frontline maintenance therapy showed significant PFS improvement in ovarian cancer patients carrying BRCA mutation
N Engl J Med
According to the preliminary data of TRITON2 study, rucaparib showed anti-tumor activity in metastatic castration-resistant prostate cancer patients carrying BRCA mutation.
Annals of Oncology
Based on data from a phase II study (B7461001), the FDA approved lorlatinib for the treatment of patients with ALK positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors (TKIs)
According to updated phase II findings presented at the 2018 ESMO Congress, infigratinib, a selective pan-FGFR kinase inhibitor, demonstrated a clinical meaningful activity in patients with IHC.
2018 ESMO Congress
This study indicated that RET fusion mutation is one of the mechanisms of drug resistance in EGFR-mutant lung cancer patients after osimertinib treatment. A combination therapy provides a new strategy to overcome the drug resistance
Piotrowska Z, et al., Cancer Discov
The U.S. FDA approves PD-1 inhibitor cemiplimab-rwlc (Libtayo) for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC).
N Engl J Med. &J Clin Oncol.
In the phase I/II TRIDENT-1 study, repotrectinib demonstrates a clinically meaningful response in non-small cell lung cancer (NSCLC) patients carrying ROS1 fusion.
The IASLC 19th World Conference on Lung Cancer
In the phase 3 ALTA-1L study, brigatinib significantly prolongs the progression-free survival (PFS) compared to crizotinib in adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC).
N Engl J Med.
There are limited treatment options in platinum-resistance/refractory ovarian cancer patients. The phase I/II TOPACIO/KEYNOTE-162 study shows that the combination of PARP inhibitor and a PD-1 inhibitor can achieve response in difficult-to treat patients.
J Clin Oncol.
The scientists analyzed the prevalence of homologous recombination–related gene mutations across 21 cancer types. The sequencing data indicated that these genes were commonly mutated in endometrial, biliary tract, and bladder cancer. The results revealed
JCO Precis Oncol.